Name: BEAM THERAPEUTICS INC (BEAM) Stock
Brand: BEAM THERAPEUTICS INC
Rating: 7 (3 reviews)

BEAM Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Zacks Investment Research - Mentions: EDIT

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

5 days ago - By: Beam Therapeutics

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

3 months ago - By: Benzinga

Is Beam Therapeutics Gaining or Losing Market Support?

5 days ago - By: Beam Therapeutics

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

7 days ago - By: Zacks Investment Research - Mentions: REGN

Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?

13 days ago - By: Zacks Investment Research - Mentions: REGN NTLA CRSP

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

14 days ago - By: The Motley Fool

Beam Therapeutics (BEAM) Earnings Transcript

14 days ago - By: Zacks Investment Research - Mentions: REGN NTLA

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

20 days ago - By: Zacks Investment Research - Mentions: REGN NTLA CRSP

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

a month ago - By: Zacks Investment Research - Mentions: REGN NTLA CRSP

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

a month ago - By: Beam Therapeutics

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

a month ago - By: Beam Therapeutics

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

a month ago - By: Zacks Investment Research - Mentions: REGN FOLD RARE

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

a month ago - By: Zacks Investment Research - Mentions: FOLD ANIP MDGL

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

a month ago - By: Zacks Investment Research - Mentions: NVO LLY FOLD

Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles

a month ago - By: Benzinga - Mentions: ADPT COIN ARKW ARKK ...

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

a month ago - By: Zacks Investment Research - Mentions: FOLD ZTS ANIP

ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down

a month ago - By: Zacks Investment Research - Mentions: NBIX FOLD XENE

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

a month ago - By: Zacks Investment Research - Mentions: IMTX

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Beam Therapeutics

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

a month ago - By: Beam Therapeutics

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

a month ago - By: Zacks Investment Research - Mentions: VRTX NTLA CRSP

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

a month ago - By: Beam Therapeutics

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

a month ago - By: Zacks Investment Research - Mentions: FOLD ANIP APLS

Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

a month ago - By: Zacks Investment Research - Mentions: AGIO ANIP NTLA

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

a month ago - By: Zacks Investment Research - Mentions: ALNY FOLD

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

a month ago - By: Zacks Investment Research - Mentions: AMRN ANIP CRMD

Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down

a month ago - By: Zacks Investment Research

Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

2 months ago - By: Zacks Investment Research

Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross

2 months ago - By: Zacks Investment Research - Mentions: REGN NTLA CRSP

BEAM THERAPEUTICS INC (BEAM) Stock News

BEAM Latest News, Press Relases and Analysis

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Is Beam Therapeutics Gaining or Losing Market Support?

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

Beam Therapeutics (BEAM) Earnings Transcript

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down

Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?